Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$70.17 USD

70.17
219,057

-1.04 (-1.46%)

Updated Oct 3, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Quest Diagnostics (DGX) Advances Transplant Testing Service

by Zacks Equity Research

These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Here's Why You Should Retain Abbott (ABT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Neogen (NEOG) Receives New Label Claims for Viroxide Super

by Zacks Equity Research

Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions

by Zacks Equity Research

Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.

Henry Schein (HSIC) Bolsters Dental Practices With AI Tools

by Zacks Equity Research

Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.

Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage

by Zacks Equity Research

With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.

Merit Medical's (MMSI) New Launch to Boost its Product Suite

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.

NuVasive's (NUVA) Precice System Cleared for Pediatric Patients

by Zacks Equity Research

NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.

Universal Health (UHS) Up 26% in 6 Months: More Room to Run?

by Zacks Equity Research

Universal Health (UHS) is well-poised for growth on the back of improved patient volumes, acquisitions and robust cash-generating abilities.

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

by Zacks Equity Research

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.

BD's (BDX) New FDA Approval to Improve Vaginitis Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.

Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines

by Zacks Equity Research

Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Shockwave Medical (SWAV) Launches New IVL Catheter in U.S.

by Zacks Equity Research

Shockwave Medical's (SWAV) latest U.S. launch is expected to serve a wider patient pool.

Here's Why You Should Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

PacBio's (PACB) Latest Offering to Enhance Genome Analysis

by Zacks Equity Research

PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a concern.

The Zacks Analyst Blog Highlights Ameriprise Financial, Everest Re Group, Microchip Technology, Henry Schein and HSBC Holdings

by Zacks Equity Research

Ameriprise Financial, Everest Re Group, Microchip Technology, Henry Schein and HSBC Holdings are part of the Zacks top Analyst Blog.

Henry Schein (HSIC) Aids Growth of Ambulatory Surgery Centers

by Zacks Equity Research

Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.

OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up

by Zacks Equity Research

OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.